The 18th Frost & Sullivan China Growth, Innovation and Leadership Summit 2024 and the 3rd New Investment Conference were held in Shanghai from August 28th to 30th, 2024. On the evening of August 28th, the 2024 Global Growth, Innovation and Leadership Awards, China Awards, and Best Practice Awards were grandly announced at the 2024 Frost & Sullivan Growth, Innovation and Leadership Awards Ceremony and VIP Reception Dinner.
Based on the research and analysis of the global cognitive impairment digital therapy market in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded the 'Global Cognitive Impairment Digital Therapy Innovation Award' to Zhejiang Brain Motion Aurora Medical Technology Co., Ltd. (hereinafter referred to as 'Brain Motion Aurora'). The award was presented by Aroop Zutshi, Global Partner and Executive Director of the Board at Frost & Sullivan, Professor Wang Yu, President of the China Hepatitis Prevention and Control Foundation and former Director of the Chinese Center for Disease Control and Prevention, to Dr. Wang Xiaoyi, CEO of Brain Motion Aurora.
Frost & Sullivan grants Zhejiang BrainLight Medical Technology Co., Ltd.
"Global Digital Therapeutics for Cognitive Disorders Innovation Award"
Aroop Zutshi, Global Partner and Executive Director of the Board at Frost & Sullivan, Professor Wang Yu, President of the China Hepatitis Prevention and Control Foundation and former Director of the Chinese Center for Disease Control and Prevention, jointly presented awards to Dr. Wang Xiaoyi, CEO of Brain Motion Aurora.
BrainGate is a leading enterprise in cognitive digital therapy in China
Since its establishment in 2012, BrainGate has been deeply involved in the field of digital therapeutics, serving as a pioneer and leader in China's digital therapy industry. The company combines brain science with artificial intelligence technology to develop digital products for cognitive impairment medical treatment. Its product pipeline covers the assessment and intervention of a wide range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, mental illnesses, and developmental defects in children. Its core product, the Brain Function Information Management Platform Software —— Liu Liu Brain Science Brain Health (hereinafter referred to as 'Liu Liu Brain') was approved for Class II medical device registration in 2018, making it one of the earliest approved digital therapy products in China.
The advantages of LiuLiBrain® digital therapy can effectively improve the treatment outcomes for patients with cognitive impairment.
The digital therapy product, LiuLiu Brain ®, under the Brain Movement Aurora brand, can assist doctors in the clinical diagnosis, treatment, and outcome assessment of patients with cognitive, speech, and psychosocial dysfunction caused by various brain injury diseases. It provides comprehensive management of cognitive language and psychological screening assessments as well as medical information on brain function data. After about a month of training, significant changes can be observed in neuropsychological data such as brain nerve fiber connectivity, electroencephalogram signals, neurotransmitter density, and clinical assessment scores. Patients also experience certain subjective changes in memory and other aspects. In 2020, the scope of LiuLiu Brain ® medical device registration has been expanded to include eight indications: vascular cognitive impairment, Alzheimer's disease, aphasia, depression, schizophrenia, sleep disorder, attention deficit hyperactivity disorder, and autism.
Propose a development strategy of 'Brain Science + AI', and build a digital therapy network for cognitive impairment
Brain Motion Aurora continues to advance the research and development of digital therapies for cognitive impairment, launching the new product 'Mind Island Aurora' in 2023. Mind Island Aurora is based on evidence-based medical evidence and can achieve AI personalized cognitive training, providing treatment for patients with depression through a game interaction mode. Focusing on the diagnosis and treatment of cognitive impairment, Brain Motion Aurora has developed multiple digital therapy products for cognitive impairment, including basic cognitive ability testing software, cognitive ability supplementary screening and assessment software, and cognitive impairment treatment software. There are also 21 products under research, which are expected to provide personalized digital treatments for patients with cognitive impairment induced by diseases such as atrial fibrillation, hypertension, coronary heart disease, and Parkinson's disease in the future.
About Frost & Sullivan Global Innovationaward
The Frost & Sullivan Global Innovation Award recognizes outstanding performance and achievements in technology innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team, through in-depth interviews, industry analysis, secondary research, and other methods, nominated a group of competitive and excellent companies to an independent judging panel. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducted a rigorous review of the companies nominated by the Frost & Sullivan team and decided to award the 'Global Digital Therapy for Cognitive Impairments Innovation Award' to Zhejiang Brain Motion Aurora Medical Technology Co., Ltd.
